This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
In an effort to boost its US presence, Sankyo licensed exclusive marketing rights here to GelTex's (developing polymer-based drugs that bind and eliminate targeted substances in the intestines) Welchol (colesevelam hydrochloride), a cholesterol-lowering drug awaiting FDA approval. It also optioned worldwide rights to a second-generation version of the drug that GelTex says is twice as potent, GT102-279, which is in Phase II trials.
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?